Annalee Armstrong
FierceBiotech
Charlottesville, VA, United States
Contact Annalee
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Annalee:
SVB capital crunch sends biotechs on bank run
Editor’s Note: Fierce Biotech is monitoring this developing story closely. See below for our latest coverage. | Silicon Valley Bank’s capital raise of $2 billion has sent shockwaves across the biotech industry and spurred a panic among some top venture capital firms that are urging their companies to withdraw deposits. → Read More
Fierce Biotech Layoff Tracker 2023: Neoleukin cuts 70% of staff, CEO; CODA shuts down
We had hoped that our Layoff Tracker would stay retired for a while. | We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. → Read More
Inovio hopes Ebola vaccine booster data can provide a shot in the arm
A day after imposing a second round of layoffs, Inovio revealed a small data set for its Ebola vaccine booster. → Read More
Inhibikase, FDA find common ground to lift hold on Parkinson's drug
After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic. | After a brief 2.5-month hold, Inhibikase Therapeutics’ Parkinson’s disease therapy is heading back to the clinic. → Read More
JPM23, Day 2: VCs still have cash to fund biotech, says investor
Welcome to Day 2 of the annual J.P. Morgan Healthcare Conference, finally back in person after a COVID-imposed virtual hiatus. | All you need to know from the second day of the J.P. Morgan Healthcare Conference. → Read More
3rd patient death potentially tied to Eisai's Alzheimer's drug reported
A third patient death potentially tied to Eisai and Biogen’s Alzheimer’s disease drug lecanemab has been reported in a phase 3 extension study, according to a → Read More
All eyes on Cytokinetics' heart failure drug as FDA seeks answers on efficacy, population and dosing
Cytokinetics will finally get the chance to make its case for its heart failure drug to the FDA's advisory committee next week. → Read More
Novartis hands steering wheel to Erasca for melanoma med in $20M licensing deal
Novartis’ naporafenib is ready for phase 2, but it won’t be heading there with the Swiss Pharma in the driver’s seat. | Novartis’ naporafenib is ready for phase 2, but it won’t be heading there with the Swiss Pharma in the driver’s seat. Instead, Erasca has signed a $20 million licensing deal to take the melanoma therapy into mid-stage development. → Read More
With a new No. 1, Avrobio hopes to get investors back on gene therapy bandwagon
It’s been a year since Avrobio's Fabry disease program failed. Now, the biotech is ready to reintroduce itself. → Read More
Roche thins Alzheimer’s program after phase 3 failure, may seek ‘external partnerships’
Roche’s Genentech unit is walking away from a clutch of studies for its leading Alzheimer’s therapy gantenerumab, weeks after the monoclonal antibody failed a pair of phase 3 studies. | Roche’s Genentech unit is walking away from a clutch of studies for its leading Alzheimer’s therapy gantenerumab, weeks after the monoclonal antibody failed a pair of phase 3 studies. → Read More
ADC's accelerated review troubles signal FDA's tough new stance on confirmatory studies
ADC Therapeutics seems to have run headlong into the FDA’s new strict policy on accelerated reviews: Get your confirmatory study in line before filing, or wait. | ADC Therapeutics seems to have run headlong into the FDA’s new strict policy on accelerated reviews: Get your confirmatory study in line before filing, or wait. → Read More
Verve's momentum slows as high cholesterol gene editing therapy placed on hold by FDA
Verve Therapeutics’ lead gene editing candidate has lost some steam after running into an FDA clinical hold. | Verve Therapeutics’ lead gene editing candidate has lost some steam after running into an FDA clinical hold. → Read More
Newly refocused Unity's ophthalmology asset improves vision in phase 2
Unity Biotechnology's treatment for diabetic macular edema improved vision in a mid-stage trial. → Read More
FDA declines to free MaaT's microbiome drug from clinical hold after a year
MaaT Pharma is not getting out from under an FDA clinical hold for its microbiome drug any time soon. | MaaT Pharma is not getting out from under an FDA clinical hold for its microbiome drug any time soon. MaaT013, in development for steroid-resistant acute graft-versus-host disease (aGvHD), was placed on hold a year ago, halting a phase 3 trial in the U.S. → Read More
Merck plans to count coughs and months until gefapixant is back in FDA hands
Merck & Co. is going to be counting coughs in the months until the P2X3 receptor antagonist medicine gefapixant is back before regulators. | Merck & Co. is going to be counting coughs and months until the P2X3 receptor antagonist medicine gefapixant is back before regulators. → Read More
Inovio cuts workforce as COVID program weighs down future growth
Inovio is reducing its workforce by 18% in a restructuring that will extend the biotech’s cash runway into 2024. → Read More
The top biotech hubs in 2022
Despite a market correction underway, a flurry of layoffs and a drop in funding and M&A across the board, there's still plenty going on in the biotech hubs around the U.S. → Read More
Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push
Galapagos CEO Paul Stoffels, M.D., has finally taken the plu | Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million). → Read More
MorphoSys finds a nice, new billion-dollar home for unwanted assets in oncology pivot
MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home, that is—as the German biotech shifts focus to oncology. | MorphoSys has found a home for a couple of assets it doesn’t want anymore—a nice billion-dollar home, that is—as the German biotech shifts focus to oncology. → Read More
Annexon is back with final Huntington's data confirming hypothesis—and no new safety issues to declare
Annexon is back with finalized data from a phase 2 Huntington's disease trial and no new safety issues to report. → Read More